In‐Hospital Death and Risk Factors in Adults With Respiratory Syncytial Virus in Spain (2016–2023). A Cross‐Sectional Study With Focus on Older Patients Authors: Fatima Valero‐Sempere, Mayarí Tortosa‐González, Silvia Otero‐Rodriguez, Maripaz Ventero, Juan Carlos Rodriguez‐Diaz, Pilar Casasnovas, Hector Pinargote‐Celorio, Rosario Sanchez‐Martinez, Esperanza Merino, Jose Manuel Ramos‐Rincon Published: 2025 ABSTRACT ABSTRACTBackground and AimsRespiratory syncytial virus (RSV) mortality varies across different populations. This study aims to assess RSV mortality in hospitalized adults (≥ 15 years) and identify key risk factors according to age.MethodsThis was a retrospective, single‐center study conducted in Alicante (Spain), including patients hospitalized for PCR‐confirmed RSV infection between 2016 and 2023. Risk factors for death were assessed using multivariable logistic regression.ResultsOf 367 patients admitted for RSV, 24 died (6.5%). Mortality was higher in very old adults (≥ 80 years, 8.9%) than in those aged under 80 years (4.8%). Significant risk factors were glomerular filtration rate (GFR) less than 38 mL/min/m2 (adjusted odds ratio [aOR] 3.15, 95% confidence interval [CI] 1.16–8.56), use of high‐flow nasal cannula (aOR 3.67, 95% CI 1.15–11.74), and metastatic cancer (aOR 10.01, 95% CI 1.28–78.55). In the group ≤ 79 years (n = 210), risk factors were non‐invasive mechanical ventilation (aOR 26.07 95% CI 2.01–338) and C‐reactive protein levels over 11 mg/dL (aOR 12.48, 95% CI 1.14–136). In the patients ≥ 80 years (n = 157; 42.8%), low GFR was associated with higher mortality (aOR 4.53, 95% CI 1.36–15.04).ConclusionRSV deaths increase with age. In‐hospital mortality was associated with non‐invasive mechanical ventilation and C‐reactive protein levels and in patients under 80, and low GFR in older patients. Introduction Respiratory syncytial virus (RSV) is a significant cause of acute lower respiratory infections, particularly affecting infants, young children, and older adults. RSV remains underdiagnosed and underrecognized in adults. Several European multicenter studies have described the epidemiology and burden of RSV in adults [1]. The RSV Consortium in Europe (RESCEU) conducted a large international prospective cohort study in community‐dwelling older adults (≥ 60 years) across several European countries, finding annual RSV infection rates of 4%–7%; most cases were mild, with very few hospitalizations or deaths [2, 3, 4]. In Spain, Heppe‐Montero et al. [5] used data from a hospital discharge database to estimate the burden of RSV‐related admissions in both pediatric and elderly populations, reporting elevated rates of hospitalization and in‐hospital mortality. RSV has increasingly been recognized as a cause of significant morbidity and mortality in adults, especially in older age groups and those with comorbid conditions. Meta‐analyses report in‐hospital case‐fatality rates of approximately 6% among adults aged ≥ 65 years in high‐income settings [6]. Individual cohort studies have identified several consistent risk factors for severe outcomes, including older age, chronic cardiac and pulmonary disease, chronic kidney disease, diabetes, and immunocompromised status [7]. One recent multicenter European cohort found an in‐hospital mortality rate of 6.6% overall, rising to 12.8% for adults requiring ICU care, with mechanical ventilation and respiratory failure among the strongest predictors [8] However, despite this growing body of evidence, data remain heterogeneous and scarce from Spain and from older adult populations (e.g., ≥ 80 years), and less is known about how risk‐factor profiles differ by older age strata [9, 10, 11, 12]. The present study addresses this gap by analyzing RSV‐related in‐hospital mortality and associated risk factors in Spanish adults, comparing patients aged < 80 years versus those ≥ 80 years. In the context of an evolving landscape of RSV detection and vaccination, estimating the true burden of RSV is now both easier and of added relevance, as this information is key to making decisions about investing health system resources in preventive interventions. On the one hand, the accelerated uptake in Spain of diagnostic molecular panels including RSV since the pandemic enables a clearer picture of RSV admissions and mortality [11]. On the other, the approval of three vaccines for RSV in Spain since 2023—GSK's Arexvy, Pfizer's Abrysvo, and Moderna's mRNA‐1345—highlights the need for health technology assessments that draw from accurate data on RSV mortality and key risk factors in different populations [11]. Therefore, this study aimed to assess RSV‐related in‐hospital mortality in adults (≥ 15 years) and compare risk factors in patients aged less than 80 years versus 80 years and older. Materials and Methods Study Design and Population This retrospective study was conducted at Dr. Balmis General University Hospital in Alicante, Spain, a tertiary hospital serving a population of approximately 260,000 people. The study included adults (aged ≥ 15 years) hospitalized from January 1, 2016 to December 31, 2023, with RSV infection confirmed by real‐time polymerase chain reaction (RT‐PCR). During the study period, criteria for admitting patients with RSV were severe cases with pneumonia, respiratory failure (O2 saturation < 95%), or mild cases with decompensation of a pre‐existing comorbidity. Data Collection and Study Variables Patient inclusion was based on data from microbiological records, and electronic medical records were reviewed using Orion Clinic version 11 and Abucasis version 0.06.01 (Conselleria de Sanitat Universal i Salut Publica, Valencia, Spain). Explanatory variables were: sociodemographics (sex, age); comorbidities; Charlson comorbidity index (dichotomized as < 7 points and ≥ 7 points); functional status, according to the Rockwood Clinical Frailty Scale (CFS) (dichotomized as no frailty [1–4 points] and mild to severe frailty [≥ 5 points]) and the Barthel index (dichotomized as no to mild dependence [60–100 points] and moderate to severe dependence [< 60 points]); severity of RSV infection (pneumonia, admission to intensive care unit [ICU], need for non‐invasive mechanical ventilation, and high‐flow nasal cannula); and laboratory parameters: creatinine, glomerular filtration rate (GFR), sodium, potassium, C‐reactive protein (CRP), and leukocytes. All these determinations were collected within the first 24 h after hospital admission. These data were dichotomized, using the 25th percentile for low GFR values and the 75th percentile for elevated levels of other values. The primary outcome was in‐hospital mortality, defined as death from any cause during hospitalization for RSV. We selected 80 years as the cutoff to define the “very old” population, following previous research conducted in Spain that also used this age threshold to characterize older adults with higher vulnerability and distinct clinical profiles. This approach is consistent with several national studies that analyzed hospital outcomes in adults aged ≥ 80 years with infectious diseases, including RSV, COVID‐19 and influenza [12, 13, 14]. Statistical Analysis Explanatory variables were categorized, stratified by age group (< 80 years vs. ≥ 80 years), and described using absolute and relative frequencies. Bivariable analyses were performed to assess crude associations with in‐hospital mortality, using the χ 2 or Fisher's exact test. Variables yielding a p‐value of less than 0.10, along with sex, were then included in a multivariable logistic regression model, which was fitted using forward stepwise selection to identify independent predictors of the outcome. A threshold of p < 0.10 was chosen given the relatively small sample size and limited number of mortality events to avoid excluding potentially relevant variables from the multivariable analysis. The overall performance of the model was assessed using the area under the curve (AUC), with values of 0.5 indicating no discriminatory ability (similar to random chance), and values of 1.0 signifying perfect discrimination. Associations were expressed as adjusted odds ratios (aOR) with 95% confidence intervals (CI). Analyses were conducted using IBM SPSS Statistics v25 (IBM Corp. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp; 2017). Ethical Considerations The Ethics Committee of Dr. Balmis General University Hospital (PI2023/103) approved the study protocol, waiving the need for informed consent due to the retrospective design. Results Of the 187,556 patients aged ≥ 15 years hospitalized during the study period, 367 were admitted with a PCR‐confirmed RSV infection: 210 were aged under 80 years, and 157 were 80 years or older. The number of annual RSV admissions showed a steady increase, except in 2020 and 2021, likely due to the SARS‐CoV‐2 pandemic and the public health measures implemented in response. Post‐pandemic, admissions rebounded, reaching 138 cases in 2023. By age group, hospitalizations with PCR‐confirmed RSV rose from 2 admissions in 2016 to 87 in 2023 among those under 80 years old, and 3 to 51 in patients 80 years and above (Figure 1). The number of RSV cases per 1000 hospitalizations in patients under 80 years was lower (0.09 cases per 1000 admissions in 2016 and 3.72 cases in 2023) than in older patients (0.65 cases in 2016 and 9.31 cases in 2023) (Figure 1). RSV‐related hospital admissions and admissions by 1.000 admission in adults aged < 80 years versus ≥ 80 years in a tertiary hospital Spain, 2016–2023. Clinical Characteristics by Age Group Table 1 presents the patient characteristics. The older age group showed a higher proportion of women (68.8% vs. 51.0%) and greater comorbidity (56.1% vs. 30.5% with a Charlson index of 7 points or more) compared to patients under 80 years old. Older patients had higher prevalence of hypertension (49.7% vs. 39.0%), chronic kidney disease (47.1% vs. 31.0%), heart failure (40.1% vs. 17.1%), diabetes mellitus (31.8% vs. 21.9%), dementia (17.2% vs. 2.9%), dependency (61.1% vs. 30.5%; p < 0.001), and frailty (72.4% vs. 37.8%), but lower prevalence of cancer (11.5% vs. 19.5%) and leukemia (0.6% vs. 5.7%). ICU admissions were also lower in the older patients (0.0% vs. 5.2%). Table 1Characteristics of adult patients (≥ 15 years) admitted for RSV infection, by age group.VariablesTotal (N = 367) n (%)≥ 80 years (N = 157) n (%)< 80 years (N = 210) n (%) p valueSexMale152 (41.4)49 (31.2)103 (49.0) 0.001 Female215 (58.6)108 (68.8)107 (51.0)ComorbiditiesCharlson index ≥ 7 points152 (41.4)88 (56.1)64 (30.5) < 0.001 Hypertension160 (43.3)78 (49.7)82 (39.0) 0.044 Pulmonary disease159 (43.3)63 (40.1)96 (45.7)0.29Chronic kidney disease139 (37.9)74 (47.1)65 (31.0) 0.002 Ever smoker128 (34.9)29 (18.5)99 (47.1) < 0.001 Anemia99 (27.0)42 (26.8)57 (27.2)0.69Chronic heart failure99 (27.0)63 (40.1)36 (17.1) < 0.001 Diabetes mellitus96 (26.2)50 (31.8)46 (21.9) 0.041 Obesity68 (18.5)26 (16.6)42 (20)0.42Cancer59 (16.1)18 (11.5)41 (19.5) 0.044 Cerebrovascular disease39 (10.6)22 (14)17 (8.1)0.086Ischemic heart disease36 (9.8)17 (10.8)19 (9)0.60Diabetes mellitus + complications33 (9.0)15 (9.6)18 (8.6)0.85Dementia33 (9.0)27 (17.2)6 (2.9) < 0.001 Immunosuppression26 (7.1)5 (3.2)21 (10)0.13Transplanted26 (7.1)0 (0)26 (12.4) < 0.001 Metastatic cancer23 (6.3)4 (2.5)19 (9) 0.015 Peptic ulcer22 (6.0)8 (5.1)14 (6.7)0.66Alcohol consumption16 (4.4)3 (1.9)13 (6.2)0.068Connective tissue disease15 (4.1)8 (5.1)7 (3.3)0.43Leukemia13 (3.6)1 (0.6)12 (5.7) 0.009 Peripheral venous disease13 (3.5)5 (3.2)8 (3.8)1.00Liver disease9 (2.5)1 (0.6)8 (3.8)0.084HIV6 (1.6)0 (0)6 (2.9) < 0.04 Lymphoma5 (1.4)1 (0.6)4 (1.9)0.40Functional statusDependency160 (43.6)96 (61.1)64 (30.5) < 0.001 Mild‐severe frailty192 (52.6)113 (72.4)79 (37.8) < 0.001 Infection severityPneumonia62 (16.9)20 (12.7)42 (20.0)0.069Respiratory failure130 (35.4)60 (38.2)70 (33.3)0.38Acute renal failure77 (21)38 (24.2)39 (18.6)0.20Non‐invasive mechanical ventilation39 (10.7)19 (12.2)20 (9.6)0.49High‐flow nasal cannula42 (11.5)22 (14.1)20 (9.6)0.19ICU admission11 (3)0 (0)11 (5.2) 0.003 Analytical parametersCreatinine > 1.4 mg/dLa 92 (25.2)43 (27.6)49 (23.4)0.40Glomerular filtration rate < 38 mL/min/m2 b 91 (24.9)47 (30.1)44 (21.1) 0.051 Sodium > 140 mmol/dLc 75 (20.5)35 (22.4)40 (19.1)0.51Potassium > 4.6 mmol/dLd 81 (22.6)44 (28.4)37 (18.1) 0.031 Ferritin > 490 mg/dLe 30 (24.4)9 (15.8)21 (31.8)0.057Procalcitonin > 0.4 mg/dLf 57 (24.6)25 (25.5)32 (23.9)0.88Leukocytes > 13 × 109 per Lg 94 (26.0)39 (25.2)55 (26.6)0.81CRP > 11 mg/dLh 99 (27.6)44 (28.6)55 (26.8)0.72EvolutionIn‐hospital mortality24 (6.5)14 (8.9)10 (4.8)0.14Length of hospital stay (days), median (IQR)4 (7–11)5 (7–10)4 (7–11)0.35 Note: Bold values indicate statistical significance.Abbreviations: CRP, C‐reactive protein; ICU, intensive care unit. a N = 365. b N = 365. c N = 365. d N = 359. e N = 123. f N = 232. g N = 362. h N = 359.John Wiley & Sons, Ltd. Characteristics of adult patients (≥ 15 years) admitted for RSV infection, by age group. Note: Bold values indicate statistical significance. Abbreviations: CRP, C‐reactive protein; ICU, intensive care unit. N = 365. N = 365. N = 365. N = 359. N = 123. N = 232. N = 362. N = 359. Mortality and Risk Factors Over the study period, 24 patients died (6.5%). Mortality was higher in patients aged ≥ 80 years compared to those < 80 years (8.9% [n = 14] vs. 4.8% [n = 10]), although the difference was not statistically significant. Table 2 presents the epidemiological characteristics of all patients who died during admission. In the multivariable model, independent risk factors for in‐hospital mortality in the whole cohort were: GFR < 38 mL (aOR 3.15, 95% CI 1.16–8.56), high‐flow nasal cannula (aOR 3.67, 95% CI 1.15–11.74) and metastatic cancer (aOR 10.01, 95% CI 1.28–78.55) (Figure 2). Age over 80 years showed a borderline significant increased risk (aOR 3.49, 95% CI 0.98–10.03). The AUC of the predictive model was 0.84 (95% CI 0.74–0.93) (Figure 4). Table 2Clinical and analytical risk factors for RSV‐related in‐hospital mortality.Variables% (n/N)OR (95% CI) p valueDemographicsAge< 80 years4.8 (10/210)10.14≥ 80 years8.9 (14/157)1.95 (0.84–4.53)SexMale7.2 (11/152)10.66Female6.0 (13/215)0.82 (0.35–1.89)ComorbiditiesCharlson index ≥ 7No5.1 (11/218)10.21Yes8.6 (13/152)1.73 (0.75–3.98)HypertensionNo8.2 (17/207)10.20Yes4.4 (7/160)0.51 (0.20–1.26)Pulmonary diseaseNo6.3 (13/208)10.83Yes6.9 (11/159)1.11 (0.49–2.55)Chronic kidney diseaseNo7.0 (16/238)10.83Yes5.8 (8/139)0.89 (0.33–1.94)SmokingNo7.5 (18/239)10.38Yes4.7 (6/128)0.60 (0.34–1.56)Chronic heart failureNo5.6 (15/268)10.24Yes9.1 (9/99)1.69 (0.71–3.98)Diabetes mellitusNo6.6 (18/271)11.00Yes6.3 (6/96)0.93 (0.36–2.43)Diabetes mellitus + complicationsNo6.0 (20/234)10.26Yes12.1 (4/32)2.16 (0.69–6.74)ObesityNo7.0 (21/299)10.57Yes4.4 (3/68)0.61 (0.17–2.11)CancerNo5.5 (17/308)10.084Yes11.9 (7/59)2.30 (0.91–5.93)Metastatic cancerNo5.8 (20/344)0.054Yes17.4 (4/2393.41 (1.06–11.0Alcohol consumptionNo6.0 (21/351)10.078Yes18.8 (3/16)3.62 (0.95–13.7)Cerebrovascular diseaseNo5.8 (19/328)10.16Yes12.8 (5/39)2.39 (0.84–6.81)DementiaNo6.3 (21/334)10.47Yes9.1 (3/33)1.49 (0.42–5.28)Functional statusDependencyNo3.4 (7/207)1 0.009 Yes10.6 (17/160)3.39 (1.37–8.40)FrailtyNo3.5 (6/173)1 0.050 Mild‐severe8.9 (17/192)2.74 (1.04–7.02)Infection severityPneumoniaNo6.9 (21/205)10.78Yes4.8 (3/62)0.69 (0.19–2.38)Non‐invasive mechanical ventilationNo5.2 (17/236)1 0.026 Yes15.4 (6/39)3.30 (1.21–8.96)High‐flow nasal cannulaNo5.0 (16/323)1 0.010 Yes16.7 (7/42)3.98 (1.47–9.98)ICU admissionNo6.5 (23/356)10.53Yes9.1 (1/11)1.44 (0.17–11.8)Laboratory parametersGFR < 38 mL/min/m2 No4.4 (12/274)1 0.013 Yes12.1 (11/91)3.00 (1.27–7.00)Sodium > 140 mmol/dLNo6.2 (18/290)10.79Yes6.7 (5/75)1.07 (0.38–3.00)Potassium > 4.6 mmol/dLNo5.0 (14/278)10.12Yes9.9 (8/81)2.06 (0.35–5.11)Leukocytes > 13 × 109/LNo4.5 (12/268)1 0.043 Yes10.6 (10/94)2.54 (1.05–6.09)CRP > 11 mg/dLNo4.6 (12/260)1 0.031 Yes11.1 (11/99)2.58 (1.1–6.06) Note: Bold values indicate statistical significance.Abbreviations: CI, confidence interval; CRP, C‐reactive protein; GFR, glomerular filtration rate; OR, odds ratio.John Wiley & Sons, Ltd. Clinical and analytical risk factors for RSV‐related in‐hospital mortality. Note: Bold values indicate statistical significance. Abbreviations: CI, confidence interval; CRP, C‐reactive protein; GFR, glomerular filtration rate; OR, odds ratio. Independent predictors of in hospital mortality from multivariable logistic‐regression analysis in overall adult's patients. CI, confidence interval; CRP, C‐reactive protein; GFR, glomerular filtration rate; OR, odds ratio. Variables were included as covariates if they showed significant associations in simple models. The 95% confidence intervals (CIs) of the odds ratios have been adjusted for multiple testing. In bold, independent predictors associated with the in‐hospital death. Table 3 outlines the risk factors for patients under 80 years old. Independent associations were observed for non‐invasive mechanical ventilation (aOR 26.07 95% CI 2.01–338.45) and C‐reactive protein levels over 11 mg/dL (aOR 12.48, 95% CI 1.14–136.11) (Figure 3a). The AUC of the predictive model was 0.84 (95% CI 0.67–1) (Figure 4). Table 3Clinical and analytical risk factors for RSV‐related in‐hospital mortality in adults aged < 80 years.Variables% (n/N)OR (95% CI) p valueDemographicsSexMale5.8 (6/103)10.53Female3.7 (4/107)0.62 (0.17–2.29)ComorbiditiesCharlson index ≥ 7No3.8 (6/156)10.28Yes7.4 (4/54)2.00 (0.54–7.37)HypertensionNo4.4 (4/82)11.00Yes4.7 (6/128)1.04 (0.28–3.81)Pulmonary diseaseNo4.4 (5/114)11.00Yes5.2 (5/96)1.19 (0.33–4.26)Chronic kidney diseaseNo5.5 (8/145)10.73Yes3.1 (2/65)0.54 (0.11–2.63)SmokingNo4.5 (5/111)11.00Yes5.1 (5/99)1.12 (0.31–4.01)Chronic heart failureNo5.2 (9/174)11.00Yes2.8 (1/36)0.52 (0.06–4.26)Diabetes mellitusNo5.5 (9/164)10.70Yes2.2 (1/46)0.38 (0.47–3.1)Diabetes mellitus + complicationsNo4.7 (9/192)10.60Yes5.6 (1/18)1.19 (0.14–10.01)ObesityNo4.8 (8/168)11.00Yes4.8 (2/42)1 (0.2–4.89)CancerNo3 (5/169)1 0.026 Yes12.2 (5/41)4.55 (1.25–16.56)Metastatic cancerNo3.7 (7/191)1 0.050 Yes15.8 (3/19)4.92 (1.17–20.92)Alcohol consumptionNo4.1 (8/197)10.12Yes15.4 (2/13)4.29 (0.81–22.69)Cerebrovascular diseaseNo5.2 (10/193)11.00Yes0 (0/17)0.93 (0.91–0.98)DementiaNo4.9 (10/204)11.00Yes0 (0/6)0.95 (0.92–0.98)Functional statusDependencyNo3.4 (5/146)10.18Yes7.8 (5/64)2.39 (0.66–8.56)FrailtyNo3.8 (5/130)10.73Mild‐severe5.1 (4/79)1.33 (0.34–5.12)Infection severityPneumoniaNo4.8 (8/168)11.00Yes4.8 (2/42)1.00 (0.2–4.89)Non‐invasive mechanical ventilationNo2.6 (5/189)1 0.006 Yes20 (4/20)9.2 (2.24–37.70)High‐flow nasal cannulaNo3.2 (6/189)1 0.044 Yes15 (3/20)5.38 (1.23–23.46)COVID infectionNo5 (10/200)11.00Yes8.9 (13/146)0.95 (0.92–0.98)ICU admissionNo4.5 (9/199)10.42Yes9.1 (1/11)2.11 (0.24–18.33)Laboratory parametersGFR < 38 mL/min/m2 No4.2 (7/165)1 0.006 Yes4.5 (2/44)1.07 (0.21–5.36)Sodium > 140 mmol/dLNo4.7 (8/168)10.52Yes2.5 (1/40)0.51 (0.06–4.24)Potassium > 4.6 mmol/dLNo3.6 (6/167)10.64Yes5.4 (2/37)1.53 (0.29–7.91)Leukocytes > 13 × 109/LNo2.6 (4/152)10.21Yes7.3 (4/55)2.90 (0.70–12.02)CRP > 11 mg/dLNo2 (3/150)1 0.013 Yes10.9 (6/55)6.00 (1.44–24.90) Note: Bold values indicate statistical significance.Abbreviations: CI, confidence interval; CRP, C‐reactive protein; GFR, glomerular filtration rate; OR, odds ratio.John Wiley & Sons, Ltd. Clinical and analytical risk factors for RSV‐related in‐hospital mortality in adults aged < 80 years. Note: Bold values indicate statistical significance. Abbreviations: CI, confidence interval; CRP, C‐reactive protein; GFR, glomerular filtration rate; OR, odds ratio. Independent predictors of in hospital mortality from multivariable logistic‐regression analysis (3a) in adult patients aged < 80 years (3b) and adult patients aged ≥ 80 years. CI, confidence interval; GFR, glomerular filtration rate; OR, odds ratio. Variables were included as covariates if they showed significant associations in simple models. The 95% confidence intervals (CIs) of the odds ratios have been adjusted for multiple testing. In bold, independent predictors associated with the in‐hospital death. Independent predictors of in hospital mortality. The overall performance of the model of independent predictors of in hospital mortality assess by the area under the curve (AUC) in overall patients, in patients aged < 80 years, in < 80 years and patients aged ≥ 80 years. Table 4 shows the risk factors for patients aged ≥ 80 years old. In the multivariable analysis, only low GFR was associated with higher mortality (aOR 4.53, 95% CI 1.36–15.04), while hypertension acted as a protective factor (aOR 0.26, 95% CI 0.07–1.03) Figure 3b). The AUC of the predictive model was 0.80 (95% CI 0.70–0.90) (Figure 4). Table 4Clinical and analytical risk factors for RSV‐related in‐hospital mortality in adults aged ≥ 80 years.Variables% (n/N)OR (95% CI) p valueDemographicsSexMale10.2 (5/49)10.77Female8.3 (9/108)0.8 (0.25–2.52)ComorbiditiesCharlson index ≥ 7No7.2 (7/97)10.39Yes11.7 (7/60)1.69 (0.56–5.10)HypertensionNo13.9 (11/79)1 0.047 Yes3.8 (3/780.24 (0.06–0.92)Pulmonary diseaseNo8.5 (8/94)11.00Yes9.5 (6/63)1.13 (0.37–3.43)Chronic kidney diseaseNo9.6 (8/83)10.79Yes8.1 (6/74)0.82 (0.27–2.5)SmokingNo10.2 (13/128)10.47Yes3.4 (1/29)0.31 (0.4–2.51)Chronic heart failureNo6.4 (6/94)10.25Yes12.7 (8/63)2.13 (0.70–6.47)Diabetes mellitusNo8.4 (9/107)10.77Yes10 (5/50)1.21 (0.38–3.81)Diabetes mellitus + complicationsNo7.7 (11/142)10.14Yes20 (3/15)2.97 (0.72–12.15)ObesityNo9.9 (13/131)10.47Yes3.8 (1/26)0.36 (0.45–2.9)CancerNo8.6 (12/139)10.66Yes11.1 (2/18)1.32 (0.27–6.45)Metastatic cancerNo8.5 (13/153)10.31Yes25 (1/4)3.59 (0.34–37.02)Alcohol consumptionNo8.4 (13/154)10.25Yes33.3 (1/3)5.43 (4.6–63.9)Cerebrovascular diseaseNo6.7 (9/135)1 0.029 Yes22.7 (5/22)4.11 (1.23–13.73)DementiaNo8.5 (11/130)10.71Yes11.1 (3/27)1.35 (0.35–5.21)Functional statusDependencyNo3.3 (2/61)10.081Yes12.5 (12/96)4.21 (0.90–19.53)FrailtyNo2.3 (1/43)10.11Mild‐severe11.5 (13/113)5.46 (0.69–43.08)Infection severityPneumoniaNo9.5 (13/137)11.00Yes5 (1/20)0.5 (0.06–4.06)Non‐invasive mechanical ventilationNo8.8 (12/137)10.68Yes10.5 (2/19)1.22 (0.25–5.95)High‐flow nasal cannulaNo7.5 (10/134)10.11Yes18.2 (4/22)2.75 (0.78–9.72)COVID InfectionNo8.9 (13/146)11.00Yes9.1 (1/11)1.02 (0.12–8.63)ICU admissionNo8.9 (14/157)——Yes——Laboratory parametersGFR < 38 mL/min/m2 No4.6 (5/109)1 0.001 Yes19.1 (9/47)4.92 (1.55–15.63)Sodium > 140 mmol/dLNo8.3 (10/121)10.80Yes11.4 (4/35)1.43 (0.42–4.88)Potassium > 4.6 mmol/dLNo7.2 (8/111)10.22Yes13.6 (6/44)2.03 (0.66–6.24)Leukocytes > 13×109/LNo6.9 (8/116)10.12Yes15.4 (6/39)2.45 (0.79–7.58)CRP > 11 mg/dLNo8.2 (9/110)10.54Yes11.4 (5/44)1.43 (0.45–4.56)Abbreviations: CI, confidence interval; CRP, C‐reactive protein; GFR, glomerular filtration rate; OR, odds ratio.John Wiley & Sons, Ltd. Clinical and analytical risk factors for RSV‐related in‐hospital mortality in adults aged ≥ 80 years. Abbreviations: CI, confidence interval; CRP, C‐reactive protein; GFR, glomerular filtration rate; OR, odds ratio. Discussion In our series, RSV admissions showed an ascending trend, interrupted by a sharp drop during the pandemic period in 2020 and 2021, when SARS‐CoV‐2 admissions were highest and related public health measures were strictest. The high number of RSV cases in 2023 may reflect a rebound effect, coupled with increased microbiological testing for respiratory viruses. Moreover, our study highlights an age‐related epidemiological difference in patients with RSV infection, with older patients showing higher morbidity and mortality. Regarding risk factors, in the overall sample, these were impaired kidney function, the need for high‐flow nasal cannula, and the presence of metastatic cancer. In patients under 80, significant risk factors included the need for non‐invasive respiratory support and elevated CRP levels. In the oldest patients, impaired kidney function was the most relevant risk factor for mortality. A progressive increase in RSV cases in adults over the study period, with a marked decrease in 2020 and 2021 and a rebound in 2023, is consistent with global epidemiological observations [15, 16]. Multiple studies have documented the knock‐on effects of non‐pharmaceutical interventions and public health measures implemented to reduce COVID‐19 infections—such as masking, social distancing, and travel restrictions—on RSV circulation in 2020 and 2021 [17, 18]. The rebound since 2022 is attributed to a larger susceptible population stemming from reduced RSV exposure during the pandemic years, as well as increased awareness and expanded microbiological testing for respiratory viruses, which contributed to higher detection rates in 2022 and 2023 [18, 19]. In addition, the number of patients tested for RSV in our microbiology laboratory also increased notably during this period (181 in 2016; 1530 in 2017; 2100 in 2018; 1239 in 2019; 1747 in 2020; 921 in 2021; 24,179 in 2022; and 14,539 in 2023), which may have further influenced the apparent rise in detected RSV cases. Consistent with our findings, several recent studies have documented a marked increase in RSV testing volumes following the COVID‐19 pandemic. For example, Singer et al. reported an increase in the percentage of acute respiratory infection episodes tested for RSV from ~1.3% in 2016–17 to ~5.9% in 2022–23 [20]. Similarly, Bonin et al. observed a more than threefold increase in RSV PCR testing after pandemic restrictions were lifted [21] These data support the interpretation that the post‐pandemic rebound in RSV positives may reflect, at least in part, enhanced diagnostic activity rather than solely viral circulation. These observations reinforce our interpretation that the post‐pandemic rise in RSV detections is at least partly attributable to expanded diagnostic testing rather than solely to increased viral circulation. Our study corroborates previous evidence on the age‐related epidemiological difference in patients with RSV infection [22, 23, 24, 25, 26]. The oldest patients showed higher morbidity as well as nearly twice the rate of in‐hospital mortality—8.9%, compared to 4.8% in those under 80. This finding is consistent with previous reports showing significantly higher in‐hospital mortality rates due to RSV in adults over 80 compared to younger populations, with estimates in the older age group ranging from 6% to over 10% [24, 25, 26]. The small sample size in this study limits the ability to identify all relevant risk factors for severe RSV outcomes in adults. However, the observed associations are consistent with the broader literature. Impaired kidney function, need for high‐flow nasal cannula therapy, and metastatic cancer have all been repeatedly identified as major risk factors for morbidity and mortality in adult RSV infection. In several studies, impaired kidney function is associated with poor outcomes, with studies demonstrating a three‐ to sevenfold higher risk compared to the general population [27, 28]. Likewise, the need for oxygen therapy reflects the severity of respiratory compromise and is a well‐established marker of poor prognosis in RSV and other viral pneumonias [12, 27, 28]. Elevated CRP levels, as observed in patients under 80 years old, are also associated with more severe disease and the need for advanced respiratory support. In this age group, the need for high‐flow nasal cannula and elevated CRP were significant predictors of adverse outcomes, aligning with findings that markers of systemic inflammation and hypoxemia are linked to disease severity in RSV infection in adults [29, 30]. Among patients over 80 years old, impaired kidney function emerges as the most relevant risk factor for mortality. This is supported by large cohort studies and meta‐analyses, which consistently show that advanced age and kidney dysfunction synergistically increase the risk of death in RSV‐infected adults. The literature also emphasizes that older adults with comorbidities, particularly chronic kidney disease, heart failure, or malignancy, are at the highest risk for severe outcomes and death [17, 28, 31, 32]. Our results identify older age (≥ 80 years) and key comorbidities as significant independent predictors of in‐hospital mortality in adults with PCR‐confirmed RSV infection. These findings are highly relevant in the Spanish context given that the NeumoExperts Prevention Group (NEP) in Spain recommends RSV vaccination for adults aged ≥ 60 years especially in the presence of chronic pulmonary, cardiovascular, renal or immunosuppressive conditions [33] As two RSV vaccines (RSVpreF (Abrysvo) and RSVpreF3 (Arexvy)) have been approved for older adults in Europe, our data support the notion that vaccination programmes targeting older adults and those with comorbidities could help reduce the burden of severe RSV outcomes, including mortality [34] Moreover, the observed higher mortality in the very‐old age group (≥ 80 years) highlights the need to prioritize vaccination and preventive measures in this particularly vulnerable subgroup. Incorporating our findings into vaccination policy discussions may aid Spanish health authorities in optimizing age thresholds, prioritization of high‐risk groups, and resource allocation for RSV prevention. This study has several limitations. First, the relatively small sample size may have limited the ability to detect additional risk factors for mortality that have been identified in other studies, due to the low number of included cases and deaths. Second, as a single‐center study, the generalizability of the findings should be interpreted with caution and within the context of the specific healthcare setting. Another important limitation is that only PCR‐confirmed RSV cases were included in the analysis. In our institution, the actual number of RSV cases may be higher, but those not confirmed by PCR were not considered for inclusion. Overall, our study shows that in‐hospital mortality due to RSV infection increases with age, particularly in patients over 80 years. In patients younger than this, metastatic cancer, respiratory failure requiring advanced respiratory support, and elevated CRP levels were significant risk factors. In contrast, for patients aged 80 and older—who often present greater comorbidity—kidney dysfunction was independently associated with an increased risk of in‐hospital death. These findings reinforce the need for heightened clinical vigilance and targeted preventive strategies, including vaccination, in adults with impaired kidney function, advanced age, and other high‐risk comorbidities. Author Contributions Fatima Valero‐Sempere: methodology and writing – original draft. Mayarí Tortosa‐González: methodology, software, data curation, investigation, and writing – original draft. Silvia Otero‐Rodríguez: methodology and investigation. Maripaz Ventero: methodology. Juan Carlos Rodríguez‐Díaz: methodology and visualization. Héctor Pinargote‐Celorio: software. Rosario Sánchez‐Martínez: methodology. Esperanza Merino: validation. José Manuel Ramos‐Rincón: data curation, investigation, formal analysis, project administration, and writing – original draft. Ethics Statement The project was approved by the ethics committee of Dr. Balmis General University Hospital (PI2023/103). The requirement for informed consent was waived since this was a retrospective study where obtaining informed consent from patients was impossible. Conflicts of Interest The authors declare no conflicts of interest. Transparency Statement The lead author Jose Manuel Ramos Rincon affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.